Dihydroxyphenylacetic Acid (DOPAC)

Dopamine is best known as a brain chemical, but your kidneys and nerves also handle large amounts of it every day. DOPAC (3,4-dihydroxyphenylacetic acid) is one of the main breakdown products your body produces when it turns over dopamine, and a portion of it leaves the body in urine.

Measuring urinary DOPAC offers a snapshot of how actively your peripheral dopamine systems are running. It is most informative when paired with other catecholamine markers, and it sits firmly in the exploratory category rather than the standard clinical toolkit.

What This Test Actually Captures

Inside cells, dopamine is broken down by two enzymes (monoamine oxidase, or MAO, and aldehyde dehydrogenase, or ALDH) into DOPAC. From there it can be further converted into another metabolite called homovanillic acid (HVA). When researchers gave people DOPAC by vein, about 40% of it showed up in urine within 24 hours, mostly as HVA, which tells you DOPAC is a short-lived intermediate that the body keeps moving through the pathway.

In the kidneys, cells in the proximal tubule pull in a dopamine precursor from the bloodstream and convert it locally, producing dopamine and then DOPAC. Some urinary DOPAC also comes from a pool already circulating in the blood that the kidneys filter and secrete. So your urine number reflects both local kidney chemistry and what is happening systemically.

Where This Sits in the Evidence

Most published research on DOPAC uses cerebrospinal fluid (the liquid around your brain and spinal cord) or blood plasma, not urine. There are no standardized clinical cutpoints for urinary DOPAC, and large outcome studies linking your urine DOPAC level to long-term disease risk or mortality have not been done. That makes this a research-grade measurement, useful for tracking change over time and for adding context to a broader catecholamine panel, rather than a number that should drive a major medical decision in isolation.

Kidney Dopamine Activity

Your kidneys make their own dopamine, which helps regulate sodium handling and blood pressure. DOPAC in urine has been used as an index of how active this local kidney dopamine system is. In a study of 19 kidney transplant recipients, urinary DOPAC rose alongside urinary dopamine and HVA as graft function recovered, and the researchers proposed urinary DOPAC as a useful marker of renal dopamine production during recovery.

What this means for you: if your urine DOPAC is unusually low and your kidney filtration markers are also off, the two findings together can point toward a kidney issue worth investigating, rather than DOPAC being interpreted on its own.

Autonomic Nervous System and Parkinsonian Conditions

Autonomic synucleinopathies are a group of conditions (including Parkinson's disease and pure autonomic failure) where the nervous system that controls automatic functions like blood pressure and digestion is damaged. In people with these conditions, urinary excretion of dopamine and norepinephrine is decreased, with related shifts in dopamine-handling pathways that suggest dysfunction in the renal sympathetic system.

The stronger evidence for DOPAC as a Parkinson's signal comes from cerebrospinal fluid, not urine. In one study of 26 at-risk individuals, low spinal fluid levels of DOPAC combined with its precursor predicted later Parkinson's disease with 75% sensitivity and 100% specificity over roughly three to four years of follow-up. Urinary DOPAC has not been shown to perform the same way, so do not use a urine result to screen for Parkinson's. It can, however, add useful context if you already have symptoms or are working with a neurologist.

Tumor Workup

Pheochromocytoma is a rare tumor of the adrenal gland that releases catecholamines and can cause severe high blood pressure. In a large study of 2,476 patients investigated over six years, urinary DOPAC was not diagnostically useful for finding pheochromocytoma. The job in that workup belongs to other markers (urinary epinephrine and norepinephrine, or plasma metanephrines). If you are being evaluated for a catecholamine-secreting tumor, DOPAC is not the test that answers the question.

Diet and Lifestyle Patterns That Show Up in DOPAC

DOPAC is also a metabolite of polyphenols found in olives. In a randomized trial of 62 mildly high-cholesterol adults, eating olive pomace-enriched biscuits (90 g per day for 8 weeks) significantly raised 24-hour urinary DOPAC, and blood DOPAC rose more than tenfold. This change reflects gut bacteria breaking down olive polyphenols, not dopamine metabolism. If you recently started a Mediterranean diet or olive-rich foods, your DOPAC can climb for reasons that have nothing to do with your nervous system.

Alcohol changes the picture too. Progressive ethanol dosing in a randomized trial of 24 adults shifted the balance of dopamine breakdown products, lowering the ratio of DOPAC to a related compound called hydroxytyrosol. The absolute effect on DOPAC is less straightforward (animal studies suggest ethanol can actually raise brain DOPAC through MAO activation), but the ratio shift in humans is consistent. The takeaway: what you ate and drank in the days before testing can move the number.

Why a Single Reading Can Fool You

A single urine DOPAC value can be pulled around by a handful of common situations. Knowing them helps you avoid acting on a number that does not reflect your usual state.

• Recent diet: olive oil, olives, and polyphenol-rich foods can raise urinary DOPAC by feeding the gut bacteria that produce it as a polyphenol metabolite, independent of dopamine activity.
• Alcohol intake: ethanol shifts dopamine breakdown, lowering the ratio of DOPAC to related compounds like hydroxytyrosol within hours to days.
• Medications acting on dopamine pathways: MAO inhibitors used for depression or Parkinson's can sharply alter DOPAC levels, and oral levodopa or dopamine precursors increase urinary DOPAC because there is simply more substrate to metabolize.
• Kidney function: because the kidneys both produce and excrete DOPAC, changes in filtration or tubular function can shift the urine number without telling you anything about dopamine activity.

Tracking Your Trend

Because urinary DOPAC has no standardized clinical cutpoint and is influenced by diet, alcohol, kidney function, and medications, any one reading is hard to interpret. The signal you are after is your own baseline and the direction your number moves over time. Get a baseline now, repeat in 3 to 6 months if you have changed your diet, alcohol intake, or medications, then check at least annually as part of a broader catecholamine or metabolic workup.

Pay attention to ratios and pattern. A drop in DOPAC alongside drops in urinary dopamine and other catecholamine metabolites tells a different story than DOPAC moving by itself. As a measurement that is still maturing clinically, building your own personal data set is the most useful thing you can do with it.

What to Do With an Unexpected Result

A single odd reading should prompt a repeat under more controlled conditions: standardized timing, avoidance of olive or polyphenol-heavy foods and alcohol for a few days before collection, and the same collection method. If the pattern persists, the next step is putting DOPAC in context, not acting on it alone.

• Companion markers: order urinary dopamine, norepinephrine, HVA, and a kidney panel (creatinine, eGFR) to see whether DOPAC is moving as part of a broader pattern or in isolation.
• Symptoms matter: if you have symptoms of autonomic dysfunction (lightheadedness on standing, abnormal sweating, slow digestion) or early Parkinsonian symptoms (tremor, stiffness, slowed movement), bring the result to a neurologist who can order targeted imaging and clinical testing.
• Suspected tumor workup: if blood pressure surges, palpitations, or severe headaches raise the question of a catecholamine-secreting tumor, ask for plasma metanephrines or fractionated urinary catecholamines instead. DOPAC is not the right tool for that question.
• Medication review: if you are on MAO inhibitors, levodopa, or other drugs affecting dopamine handling, the result is expected to be off and should be interpreted with your prescribing clinician.